United Kingdom Osteoporosis Treatment Market to be Dominated by Bisphosphonate through 2028
The increasing incidence of osteoporosis
fractures is expected to drive the growth of United Kingdom osteoporosis
treatment market in the forecast period, 2024-2028.
According to TechSci Research
report, “United Kingdom Osteoporosis
Treatment Market
- By Region, Competition, Forecast and Opportunities, 2018-2028”, United Kingdom osteoporosis treatment market is anticipated to grow at
an impressive rate in the forecast period, 2024-2028. It can be ascribed
to the rising demand for diagnostic tests with medical benefits such as
managing health issues like early detection and diagnosis, accurate diagnosis,
tailored treatment plans, monitoring treatment efficacy, along with growing
preference for efficiency and safety among people facing bone related issues,
across the region. Additionally, rapid advances in science and technology,
increasing healthcare expenditure, changes in food habits, change in lifestyle,
burgeoning aging population, and rising interest in avoiding osteoporosis
through diagnostics will escalate the growth of United Kingdom osteoporosis
treatment market in coming years. Besides, emergence of new product development
in the field of osteoporosis treatment such as anabolic agents, long-acting formulations,
combination therapies, and digital health solutions will further be expected to
support the United Kingdom osteoporosis treatment market growth.
However, the diagnosing of osteoporosis in United
Kingdom can be complex, and there are many individuals who are not aware of
their condition, or healthcare professionals may not prioritize osteoporosis
screening or treatment which can slow down the growth of United Kingdom osteoporosis
treatment market in the forecast period. Similarly, there are many patients who
may not fully adhere to their medication regimens or fail to make necessary
lifestyle modifications. Poor treatment adherence can impact the effectiveness
of therapy and increase the risk of fractures which may hamper the United
Kingdom osteoporosis treatment market growth, during the forecast period. Also,
The United Kingdom's healthcare system is composed of various stakeholders,
including the National Health Service (NHS) and private healthcare providers.
The fragmentation of the system can create challenges in coordinating care,
ensuring consistent treatment guidelines, and optimizing patient outcomes
across different healthcare settings which can further restrict the growth of United
Kingdom osteoporosis treatment market.
Browse over XX market data
Figures spread through XX
Pages and an in-depth TOC on " United Kingdom Osteoporosis Treatment Market.”
The
United Kingdom osteoporosis treatment market can be segmented by drug class,
route of administration, application, and by region. Based on drug class, the United
Kingdom osteoporosis treatment market can be segmented into parathyroid hormone therapy,
bisphosphonates, calcitonin, RANKL inhibitors, and others. The bisphosphonates
segment dominated the market in 2022 and is expected to continue maintaining
its dominance throughout the forecast period. It can be ascribed to increasing
demand for commonly prescribed bisphosphonates including alendronate,
risedronate, ibandronate, and zoledronic acid. These medications are typically
taken orally, although zoledronic acid is administered intravenously once a
year across the region.
Based on route of
administration, the market can be segmented into oral, parental, and others. The oral segment is expected to
dominate during the forecast period. Oral medications are commonly prescribed
and widely used due to their convenience, ease of administration, and patient
preference. Many osteoporosis medications, including bisphosphonates such as
alendronate and risedronate, selective estrogen receptor modulators such as
raloxifene, and calcium/vitamin D supplements, are available in oral forms.
Major companies operating in United
Kingdom osteoporosis treatment market are:
- P GlaxoSmithKline Ltd
- AstraZeneca Ltd
- Amgen Ltd
- Eli Lilly & Co
- Pfizer Ltd
- Novartis Ltd
- Merck & Co.
- UCB Pharma Ltd
- Johnson & Johnson Ltd
- Servier Pharmaceuticals
LLC/United Kingdom
In 2011, Novartis acquired
Alcon, a multinational eye care company. While Alcon's focus is primarily on
eye care, the acquisition expanded Novartis' presence in the healthcare market,
potentially influencing their offerings in areas such as osteoporosis
treatment.
In 2020, the University of
Southampton and UCB Pharma collaborated on a research project to investigate
the role of a specific protein in bone regeneration and repair. The partnership
aimed to gain insights into the mechanisms of bone healing and potentially
develop new treatments for osteoporosis-related fractures.
In 2018, the University of
Sheffield and GSK announced a collaboration to develop new treatments for
musculoskeletal conditions, including osteoporosis. The partnership aimed to
combine the university's research expertise in bone biology with GSK's drug
discovery and development capabilities.
Download Free Sample Report
Customers
can also request for 10% free customization on this report.
“United Kingdom osteoporosis
treatment is expected to dominate the market during the forecast period on
account due to the rising demand for diagnostic testing with medical benefits
along with growing preference for oral medications across the region.
Furthermore, trend of use of wearable devices is growing, particularly among
individuals with bone-related medical conditions, where generic treatment is available
which will further contribute to demand for United Kingdom osteoporosis
treatment market during the forecast period. Besides, increasing concern about
healthy lifestyles, increasing expenditure on health and wellness is further
expected to create lucrative opportunities for the market growth.” said Mr.
Karan Chechi, Research Director with TechSci Research, a research based global
management consulting firm.
“United
Kingdom Osteoporosis Treatment Market By Drug Class (Parathyroid Hormone
Therapy, Bisphosphonates, Calcitonin, RANKL Inhibitors, and Others), By Route
of Administration (Oral, Parental, and Others), By Application (Primary
Osteoporosis, Secondary Osteoporosis), By Region, Competition, Forecast &
Opportunities, 2028F”,
has evaluated the future growth potential of United Kingdom Osteoporosis
Treatment Market and provides statistics & information on market size,
structure, and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in United Kingdom Osteoporosis
Treatment.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com